French private equity firm Turenne Capital has acquired a majority stake in biomarker analysis specialist ABL Lyon from Institut Merieux.
French private equity firm Turenne Capital has acquired a majority stake in biomarker analysis specialist ABL Lyon from Institut Merieux.